Chitosan⁻Zinc(II) Complexes as a Bio-Sorbent for the Adsorptive Abatement of Phosphate: Mechanism of Complexation and Assessment of Adsorption Performance.

This study examines zinc(II)⁻chitosan complexes as a bio-sorbent for phosphate removal from aqueous solutions. The bio-sorbent is prepared and is characterized via Fourier Transform Infrared Spectroscopy (FT-IR), Scanning Electron Microscopy (SEM), and Point of Zero Charge (pHPZC)⁻drift method. The adsorption capacity of zinc(II)⁻chitosan bio-sorbent is compared with those of chitosan and ZnO⁻chitosan and nano-ZnO⁻chitosan composites. The effect of operational parameters including pH, temperature, and competing ions are explored via adsorption batch mode. A rapid phosphate uptake is observed within the first three hours of contact time. Phosphate removal by zinc(II)⁻chitosan is favored when the surface charge of bio-sorbent is positive/or neutral e.g., within the pH range inferior or around its pHPZC, 7. Phosphate abatement is enhanced with decreasing temperature. The study of background ions indicates a minor effect of chloride, whereas nitrate and sulfate show competing effect with phosphate for the adsorptive sites. The adsorption kinetics is best described with the pseudo-second-order model. Sips (R² > 0.96) and Freundlich (R² ≥ 0.95) models suit the adsorption isotherm. The phosphate reaction with zinc(II)⁻chitosan is exothermic, favorable and spontaneous. The complexation of zinc(II) and chitosan along with the corresponding mechanisms of phosphate removal are presented. This study indicates the introduction of zinc(II) ions into chitosan improves its performance towards phosphate uptake from 1.45 to 6.55 mg/g and provides fundamental information for developing bio-based materials for water remediation.

MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas.

Uterine leiomyomas, or fibroids, are benign tumors that affect millions of women worldwide and that can cause considerable morbidity. To study the genetic basis of this tumor type, we examined 18 uterine leiomyomas derived from 17 different patients by exome sequencing and identified tumor-specific mutations in the mediator complex subunit 12 (MED12) gene in 10. Through analysis of 207 additional tumors, we determined that MED12 is altered in 70% (159 of 225) of tumors from a total of 80 patients. The Mediator complex is a 26-subunit transcriptional regulator that bridges DNA regulatory sequences to the RNA polymerase II initiation complex. All mutations resided in exon 2, suggesting that aberrant function of this region of MED12 contributes to tumorigenesis.